Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STB-636
- Development stage
- Preclinical
- Lead developer
- Stoked Bio
- Modality
- Small Molecules
01
Overview
STB-636 is an investigational small molecule antifungal agent being developed by Stoked Bio for the treatment of invasive candidiasis. Discovered using the company's proprietary biology-first, AI-mediated MOSAIC™ platform, STB-636 is designed to selectively target Candida albicans. The program is currently in the lead optimization stage of preclinical development under Stoked Bio's 'Microbiome Calibration™' platform, which focuses on modulating the microbiome to address complex diseases.
Beyond the preview
Go deeper on STB-636.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STB-636.